Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBIT (2023 - 2025)

Contineum Therapeutics has reported EBIT over the past 3 years, most recently at -$17.1 million for Q4 2025.

  • Quarterly results put EBIT at -$17.1 million for Q4 2025, changed 0.4% from a year ago — trailing twelve months through Dec 2025 was -$68.1 million (down 33.72% YoY), and the annual figure for FY2025 was -$68.1 million, down 33.73%.
  • EBIT for Q4 2025 was -$17.1 million at Contineum Therapeutics, down from -$14.9 million in the prior quarter.
  • Over the last five years, EBIT for CTNM hit a ceiling of $38.9 million in Q2 2023 and a floor of -$18.1 million in Q1 2025.
  • Median EBIT over the past 3 years was -$12.0 million (2024), compared with a mean of -$8.6 million.
  • Biggest five-year swings in EBIT: crashed 128.11% in 2024 and later decreased 0.4% in 2025.
  • Contineum Therapeutics' EBIT stood at -$9.7 million in 2023, then plummeted by 76.18% to -$17.0 million in 2024, then fell by 0.4% to -$17.1 million in 2025.
  • The last three reported values for EBIT were -$17.1 million (Q4 2025), -$14.9 million (Q3 2025), and -$17.9 million (Q2 2025) per Business Quant data.